Xintela AB (publ) (XINT.ST)

SEK 0.32

(-0.63%)

Market Cap (In SEK)

180.86 Million

Revenue (In SEK)

78 Thousand

Net Income (In SEK)

-54.08 Million

Avg. Volume

441.26 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.204-0.65
PE
-
EPS
-
Beta Value
1.758
ISIN
SE0007756903
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D.
Employee Count
-
Website
https://www.xintela.se
Ipo Date
2016-03-22
Details
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.